Clinical Characteristics, Outcomes, and Risk Factors for Adverse Events in Elderly and Non-Elderly Japanese Patients With Non-Valvular Atrial Fibrillation　― Competing Risk Analysis From the Hokuriku-Plus AF Registry ―

Figures

• 

  Figure 1.. Results of the Gray test for the incidence of (A) thromboembolism and (B) major bleeding in elderly (age ≥75 years) and non-elderly (age <75 years) patients with non-valvular atrial fibrillation (NVAF).

• 

  Figure 2.. Incidence of major bleeding by HAS-BLED scores in elderly and non-elderly patients with non-valvular atrial fibrillation (NVAF).

• 

  Figure 3.. Results of the Gray test for the cumulative incidence of (A,C) thromboembolism and (B,D) major bleeding in non-elderly (age <75 years; A,B) and elderly (age ≥75 years; C,D) patients with non-valvular atrial fibrillation (NVAF) according to warfarin or direct oral anticoagulant (DOAC) use considering the competing risk of death.

• 

  Figure 4.. Results of the Gray test for the incidence of (A) thromboembolism and (B) major bleeding in elderly (age ≥75 years) and non-elderly (age <75 years) non-valvular atrial fibrillation (NVAF) patients using direct oral anticoagulants (DOACs).